tiprankstipranks
Primo Nutraceuticals (BUGVF)
OTHER OTC:BUGVF
US Market

Primo Nutraceuticals (BUGVF) Stock Price & Analysis

8 Followers

BUGVF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.11 - $0.11
Previous Close$0.11
Volume5.00K
Average Volume (3M)N/A
Market Cap
$26.00
Enterprise Value$333.49K
Total Cash (Recent Filing)C$9.95K
Total Debt (Recent Filing)C$465.93K
Price to Earnings (P/E)N/A
Beta0.80
Jul 01, 2020
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,094,739
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation7.38
R-Squared0.02
Alpha1.59
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

37.58%0.00%0.00%62.42%
37.58%
Insiders
0.00% Other Institutional Investors
62.42% Public Companies and
Individual Investors

BUGVF FAQ

What was Primo Nutraceuticals’s price range in the past 12 months?
Primo Nutraceuticals lowest stock price was $0.11 and its highest was $0.11 in the past 12 months.
    What is Primo Nutraceuticals’s market cap?
    Currently, no data Available
    When is Primo Nutraceuticals’s upcoming earnings report date?
    Primo Nutraceuticals’s upcoming earnings report date is Jul 01, 2020 which is 1413 days ago.
      How were Primo Nutraceuticals’s earnings last quarter?
      Primo Nutraceuticals released its earnings results on Feb 20, 2020. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
        Is Primo Nutraceuticals overvalued?
        According to Wall Street analysts Primo Nutraceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Primo Nutraceuticals pay dividends?
          Primo Nutraceuticals does not currently pay dividends.
          What is Primo Nutraceuticals’s EPS estimate?
          Primo Nutraceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Primo Nutraceuticals have?
          Primo Nutraceuticals has 25,982,012 shares outstanding.
            What happened to Primo Nutraceuticals’s price movement after its last earnings report?
            Primo Nutraceuticals reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Primo Nutraceuticals?
              Currently, no hedge funds are holding shares in BUGVF
              ---

              Primo Nutraceuticals Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Primo Nutraceuticals

              Primo Nutraceuticals Inc is engaged in the production, processing, retail and branding of cannabis and cannabis related products. The company offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              VolitionRX
              Cannabis Sativa
              CV Sciences
              MediPharm Labs
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis